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The time has passed when immunology was just another basic science discipline
in the first years of medical school that students needed to memorize enough to pass
examinations and not to worry much thereafter depending on the specialty pursued.
Nowadays, the understanding of immunological mechanisms is increasingly essential
in many disciplines because most diseases have a component of inflammatory
response along side the inciting agent as part of the pathogenesis of their clinical
manifestations and also as part of tissue repair from damage. Besides the involvement
of the immune system in diseases of other organ systems, many new immunological
diseases have been recognized from deficient, exaggerated and misdirected
immunological responses. The detailed knowledge of immunological mechanism of
disease pathogenesis down to molecular mechanisms has been possible because of
the tremendous advances in basic immunology and application of that knowledge and
tools to patients.
 Immunology-based therapies account for major advances in medicine (Table
1). Over a century ago when immunology was in its birth, scientists were already
using killed microbes as vaccines and heterologous antibodies as antidotes. Despite
rudimentary knowledge of the mechanisms of those treatments, physicians had
remarkable successes and many of those treatments are still used today in refined
forms. Killed microbes or parts of them are used in vaccines, which are highly successful
to prevent infectious. Indeed, vaccines are the most important advance in medicine
for its role in markedly preventing morbidity and mortality worldwide, particularly in
children, caused by infectious diseases including poliomyelitis, measles, mumps,
diphtheria, tetanus, varicella, influenza, hepatitis A and B, yellow fever, rabies and
invasive bacterial infections caused by Haemophilus influenzae, meningococci and
Streptococcus pneumoniae. Still, enormous challenges lie ahead such as malaria,
tuberculosis and HIV infection. Since 1911, vaccines have also been successful in
secondary prevention of symptoms in already established disease as in the case of
IgE-mediated hypersensitivity respiratory allergies, and later, insect anaphylaxis.
Vaccines prime the immune system to respond to infectious agents so that when an
infection occurs, it elicits a fast and intense memory immune response that clears the
infection. In the case of allergic diseases, vaccines modify the exaggerated
hypersensitivity immune response to an attenuated and less damaging response.
(1) Prof. Assitente – Divisão de Alergia – UCSF – California - EUA.
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Table 1 - Immune-based treatments in clinical use
Drug Type Mechanism of Action Indications
Vaccines Proteins Induce primary immune Prevention of infectious
response or alter IgE-mediated diseases and treatment for
hypersensitivity responses. respiratory and insect IgE-
mediated allergies.
Antiserum Heterologous Binding and neutralization Snake and insect bites and
polyclonal antibody of toxin. poisoning.
Glucocorticoids Small molecules Inhibits several inflammatory Auto-immune and
mediators. hypersensitivity disorders
Non-steroidal anti- Small molecules Inhibits prostaglandins. Analgesia and
inflammatory drugs inflammatory conditions.
Immunosuppressants: Small molecules Inhibits calcineurin and Auto-immune diseases
Calcineurin inhibitors transcription factors in T cells. and graft rejection.
(cyclosporine, tacrolimus)
Immunosuppressants:
DNA metabolism Small molecules Methotrexate inhibits folate Rheumatoid arthritis and
inhibitors metabolism, azathioprine and graft rejection.
mycophenolate inhibit
nucleotide metabolism.
Immunoglobulins Polyclonal IgG Binding to antigen, and in high Replacement in antibody
purified from donors doses, inhibits autoantibodies. deficiency, and few
autoimmune diseases.
Interferons alpha, beta Recombinant Stimulate interferon receptors. Chronic hepatitis B and C,
and gamma proteins multiple sclerosis, and
chronic granulomatous
disease, respectively.
Granulocyte colony Recombinant G-CSF stimulates neutrophil Neutropenia.
stimulating factor protein production in bone marrow.
Interleukin 11 Recombinant IL-11 stimulates platelet Thrombocytopenia
protein  production in bone marrow.
Leukotriene antagonists Small molecule Inhibit binding to receptors or Asthma and allergic
synthesis. rhinitis.
Anti-CD3 Murine monoclonal Binds to CD3 and kills T cells. Graft rejection.
antibody
Anti-IgE Humanized Binds to IgE and prevents Asthma.
monoclonal antibody binding to its receptor. Rheumatoid arthritis
TNFa antagonists: E is a fusion protein Binds to TNFa and and Crohn’s disease.
(Ethercept[E] and of TNFa receptor prevents binding to its
remidcade [R]) and  Fc IgG1. receptor.
Interleukin 1 R is a humanized Binds to IL-1 and prevents Rheumatoid arthritis.
receptor antagonist monoclonal antibody binding to its receptor.
Recombinant protein
Interleukin 2 receptor Fusion protein of Binds to CD25 (IL-2Ra) CD25(+) persistent
antagonists (Denileukin diphtheria toxins A bearing T cells killing them. cutaneous T-cell lymphoma
diflitox [D] and and B and interleukin [D], and renal transplant
basiliximab [B])  2 (D). Humanized rejection (B).
monoclonal antibody
to CD25 (B)
Anti-CD52 Humanized Binds to CD52 on normal Refractory B-cell chronic
(Alemtuzumab) monoclonal  antibody and malignant B and T lymphocytic leukemia.
cells, NK cells, monocytes,
 and macrophages.
Anti-CD33 Fusion protein of Binds to CD33 on leukemic Refractory CD33 positive
(Gemtuzumab) humanized blasts and immature normal  acute myeloid leukemia.
monoclonal IgG4 myelomonocytic cells.
and calicheamicin
TNF: Tumor necrosis factor. Sources: http://www.fda.gov/cber/label/label.htm
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Besides using the etiological agents to alter immune system as therapeutic tools,
many decades ago physicians were also using another immunological therapy:
antibodies.  Antiserum developed in animals against specific toxins and used in patients
was once thought to potentially cure many diseases, but soon hypersensitivity reactions
to these treatments with repeated used (e.g. serum-sickness) precluded their use in
recurrent or chronic diseases.  However, still today, antiserum to snake and arachnid
venoms are used clinically. Advances in immunology and biochemistry of protein
synthesis have allowed modification of these treatments and repeated use. Instead of
polyclonal antibodies, we now use monoclonal antibodies made in animals, and in
addition, amino acids are changed to those of human immunoglobulins except for the
amino acids that significantly impair binding affinity to the antigen. As a result, these
humanized monoclonal antibodies have 95% or more of human amino acid sequences
and are less immunogenic themselves allowing chronic repeated use. Therefore,
clinicians now can now treat chronic or recurrent diseases with antibodies, such as
using anti-IgE to treat asthma.
Advances in basic sciences led to development of other targeted treatments.
Advances in biochemistry and biophysics allow scientists to determine the three-
dimensional structure of proteins and the exact binding sites between soluble ligands
and their receptors, or between surface proteins. This knowledge is essential for
scientists to design small molecules able to block binding and downstream signals
(e.g. inhibition of binding between adhesion molecules). Advances in immunology
helped us understand that soluble receptors are natural inhibitors, which are now
used therapeutically (e.g. interleukin 1 and TNF alpha inhibitors). Advances in genetics
led to recombinant DNA technology and synthesis of human proteins in the laboratory
for therapeutic use (e.g. interleukin 2). Advances in pharmacology have improved
pharmacokinetic and pharmacodynamic profile of therapeutic agents (e.g. peglated
interferon). Taken together, all these advances have allowed deep and detailed
understanding of immunological mechanisms in the pathogenesis of diseases, which
is now being exploited to develop therapies targeting specific immunological molecules
or specific immune effector functions to treat patients with allergic, infectious, neoplastic
and autoimmune disorders.
It has taken several decades for the tremendous advances in basic immunology
to be translated into new treatments. However, biotechnology today allows this path to
be completed at a faster pace.  New molecules or pathways discovered in basic science
can be investigated in disease and new treatments developed in few years. Today, a
large portfolio of new drug development in traditional pharmaceutical companies and
new biotechnology companies involve biological agents, many designed to alter the
immune system. So, the medical student today needs to develop a solid understanding
in immunology to be able to properly treat patients when they finish their medical
training.
